GRIFOLS S A/S (NASDAQ:GRFS) was downgraded by equities researchers at Berenberg Bank from a “buy” rating to a “hold” rating in a note issued to investors on Friday, The Fly reports.
Several other equities analysts have also weighed in on GRFS. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, December 18th. BidaskClub lowered shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, January 30th. Finally, Morgan Stanley decreased their target price on shares of GRIFOLS S A/S from $20.00 to $19.00 and set an “underweight” rating for the company in a report on Wednesday, January 2nd. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. GRIFOLS S A/S presently has a consensus rating of “Hold” and a consensus target price of $21.00.
NASDAQ:GRFS opened at $19.21 on Friday. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $24.97. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.78 and a quick ratio of 1.07. The stock has a market cap of $12.88 billion, a PE ratio of 17.46, a price-to-earnings-growth ratio of 1.28 and a beta of 1.07.
A number of institutional investors and hedge funds have recently modified their holdings of GRFS. Harding Loevner LP raised its position in GRIFOLS S A/S by 477.5% during the third quarter. Harding Loevner LP now owns 89,561,714 shares of the biotechnology company’s stock valued at $272,368,000 after acquiring an additional 74,051,933 shares in the last quarter. AKO Capital LLP bought a new position in GRIFOLS S A/S during the first quarter valued at approximately $36,979,000. FMR LLC raised its position in GRIFOLS S A/S by 92.1% during the third quarter. FMR LLC now owns 13,763,759 shares of the biotechnology company’s stock valued at $294,132,000 after acquiring an additional 6,600,205 shares in the last quarter. Credit Suisse AG raised its position in GRIFOLS S A/S by 122.2% during the third quarter. Credit Suisse AG now owns 8,680,622 shares of the biotechnology company’s stock valued at $138,629,000 after acquiring an additional 4,774,171 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its position in GRIFOLS S A/S by 22.1% during the second quarter. Artisan Partners Limited Partnership now owns 19,140,903 shares of the biotechnology company’s stock valued at $319,079,000 after acquiring an additional 3,465,799 shares in the last quarter. 19.56% of the stock is currently owned by hedge funds and other institutional investors.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Article: Marijuana Stocks Future Looks Bright
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.